Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines.

Goswami R, Chatzikleanthous D, Lou G, Giusti F, Bonci A, Taccone M, Brazzoli M, Gallorini S, Ferlenghi I, Berti F, O'Hagan DT, Pergola C, Baudner BC, Adamo R.

ACS Infect Dis. 2019 Sep 13;5(9):1546-1558. doi: 10.1021/acsinfecdis.9b00084. Epub 2019 Jul 23.

PMID:
31290323
2.

Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota.

Naili I, Vinot J, Baudner BC, Bernalier-Donadille A, Pizza M, Desvaux M, Jubelin G, D'Oro U, Buonsanti C.

Vaccine. 2019 Jan 7;37(2):314-324. doi: 10.1016/j.vaccine.2018.10.008. Epub 2018 Nov 30.

3.

Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.

Vo HTM, Baudner BC, Sammicheli S, Iannacone M, D'Oro U, Piccioli D.

Front Immunol. 2018 Apr 9;9:641. doi: 10.3389/fimmu.2018.00641. eCollection 2018.

4.

Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.

Misiak A, Leuzzi R, Allen AC, Galletti B, Baudner BC, D'Oro U, O'Hagan DT, Pizza M, Seubert A, Mills KHG.

Vaccine. 2017 Sep 18;35(39):5256-5263. doi: 10.1016/j.vaccine.2017.08.009. Epub 2017 Aug 18.

5.

Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine.

Donadei A, Balocchi C, Romano MR, Panza L, Adamo R, Berti F, O'Hagan DT, Gallorini S, Baudner BC.

Vaccine. 2017 Jul 13;35(32):3930-3937. doi: 10.1016/j.vaccine.2017.06.018. Epub 2017 Jun 20.

PMID:
28645718
6.

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U.

Sci Rep. 2016 Jul 21;6:29063. doi: 10.1038/srep29063.

7.

The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.

Donadei A, Balocchi C, Mancini F, Proietti D, Gallorini S, O'Hagan DT, D'Oro U, Berti F, Baudner BC, Adamo R.

Eur J Pharm Biopharm. 2016 Oct;107:110-9. doi: 10.1016/j.ejpb.2016.07.004. Epub 2016 Jul 5.

PMID:
27388628
8.

The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine.

Bruno C, Agnolon V, Berti F, Bufali S, O'Hagan DT, Baudner BC.

Eur J Pharm Biopharm. 2016 Aug;105:1-8. doi: 10.1016/j.ejpb.2016.05.013. Epub 2016 May 17.

PMID:
27224856
9.

Positive Contribution of Adjuvanted Influenza Vaccines to the Resolution of Bacterial Superinfections.

Zurli V, Gallotta M, Taccone M, Chiarot E, Brazzoli M, Corrente F, Bonci A, Casini D, De Gregorio E, Baudner BC, Bertholet S, Seubert A.

J Infect Dis. 2016 Jun 15;213(12):1876-85. doi: 10.1093/infdis/jiw048. Epub 2016 Feb 9.

PMID:
26908732
10.

Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines.

Agnolon V, Bruno C, Galletti B, Mori E, Ugozzoli M, Pergola C, O'Hagan DT, Baudner BC.

Vaccine. 2016 Feb 17;34(8):1040-6. doi: 10.1016/j.vaccine.2016.01.012. Epub 2016 Jan 17.

PMID:
26784684
11.

CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Lazzaro S, Giovani C, Mangiavacchi S, Magini D, Maione D, Baudner B, Geall AJ, De Gregorio E, D'Oro U, Buonsanti C.

Immunology. 2015 Oct;146(2):312-26. doi: 10.1111/imm.12505. Epub 2015 Aug 28.

12.

The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.

Agnolon V, Bruno C, Leuzzi R, Galletti B, D'Oro U, Pizza M, Seubert A, O'Hagan DT, Baudner BC.

Int J Pharm. 2015 Aug 15;492(1-2):169-76. doi: 10.1016/j.ijpharm.2015.06.030. Epub 2015 Jul 3.

PMID:
26149936
13.

Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.

Bonificio A, Ghartey-Tagoe E, Gallorini S, Baudner B, Chen G, Singh P, O'Hagan DT, Kommareddy S.

Vaccine. 2015 Jun 9;33(25):2930-8. doi: 10.1016/j.vaccine.2015.04.059. Epub 2015 Apr 27.

PMID:
25930118
14.

Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen.

Donadei A, Gallorini S, Berti F, O'Hagan DT, Adamo R, Baudner BC.

Mol Pharm. 2015 May 4;12(5):1662-72. doi: 10.1021/acs.molpharmaceut.5b00072. Epub 2015 Apr 20.

PMID:
25867449
15.

Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.

Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O'Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3680-5. doi: 10.1073/pnas.1424924112. Epub 2015 Mar 9.

16.

Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.

Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A, Kommareddy S, Bertholet S, O'Hagan DT, Baudner BC.

Vaccine. 2014 Apr 25;32(20):2382-8. doi: 10.1016/j.vaccine.2013.12.043. Epub 2014 Jan 13.

PMID:
24434044
17.

Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, Veggi D, Pansegrau W, Fiaschi L, Savino S, Swennen E, Cakici O, Oviedo-Orta E, Giraldi M, Baudner B, D'Urzo N, Maione D, Soriani M, Rappuoli R, Pizza M, Douce GR, Scarselli M.

Infect Immun. 2013 Aug;81(8):2851-60. doi: 10.1128/IAI.01341-12. Epub 2013 May 28.

18.

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A.

Vaccine. 2013 Jul 18;31(33):3363-9. doi: 10.1016/j.vaccine.2013.05.007. Epub 2013 May 16.

PMID:
23684834
19.

Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs.

Kommareddy S, Baudner BC, Bonificio A, Gallorini S, Palladino G, Determan AS, Dohmeier DM, Kroells KD, Sternjohn JR, Singh M, Dormitzer PR, Hansen KJ, O'Hagan DT.

Vaccine. 2013 Jul 25;31(34):3435-41. doi: 10.1016/j.vaccine.2013.01.050. Epub 2013 Feb 8.

PMID:
23398932
20.

Preparation of highly concentrated influenza vaccine for use in novel delivery approaches.

Kommareddy S, Bonificio A, Gallorini S, Baudner B, Singh M, O'Hagan D.

J Pharm Sci. 2013 Mar;102(3):866-75. doi: 10.1002/jps.23444. Epub 2013 Jan 9.

PMID:
23303584
21.

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.

Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, Hawkins LD, Otten G, O'Hagan DT.

Hum Vaccin Immunother. 2012 Apr;8(4):486-90. doi: 10.4161/hv.19229.

PMID:
22832252
22.

MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.

Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E.

J Immunol. 2012 Apr 1;188(7):3088-98. doi: 10.4049/jimmunol.1101764. Epub 2012 Feb 20.

23.

Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.

Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'Hagan DT.

J Pharm Sci. 2012 Mar;101(3):1021-7. doi: 10.1002/jps.23019. Epub 2011 Dec 20.

PMID:
22190403
24.

An alternative renewable source of squalene for use in emulsion adjuvants.

Brito LA, Chan M, Baudner B, Gallorini S, Santos G, O'Hagan DT, Singh M.

Vaccine. 2011 Aug 26;29(37):6262-8. doi: 10.1016/j.vaccine.2011.06.067. Epub 2011 Jun 30.

PMID:
21723355
25.

Designing the next generation of vaccines for global public health.

Bagnoli F, Baudner B, Mishra RP, Bartolini E, Fiaschi L, Mariotti P, Nardi-Dei V, Boucher P, Rappuoli R.

OMICS. 2011 Sep;15(9):545-66. doi: 10.1089/omi.2010.0127. Epub 2011 Jun 17. Review.

PMID:
21682594
26.

Combination vaccines.

Skibinski DA, Baudner BC, Singh M, O'Hagan DT.

J Glob Infect Dis. 2011 Jan;3(1):63-72. doi: 10.4103/0974-777X.77298.

27.

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A.

Vaccine. 2011 Feb 17;29(9):1812-23. doi: 10.1016/j.vaccine.2010.12.090. Epub 2011 Jan 6.

PMID:
21215831
28.

Bioadhesive delivery systems for mucosal vaccine delivery.

Baudner BC, O'Hagan DT.

J Drug Target. 2010 Dec;18(10):752-70. doi: 10.3109/1061186X.2010.529143. Epub 2010 Nov 2. Review.

PMID:
21039314
29.

Determining the activity of mucosal adjuvants.

Baudner BC, Giudice GD.

Methods Mol Biol. 2010;626:261-85. doi: 10.1007/978-1-60761-585-9_18.

PMID:
20099134
30.

Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.

Dormitzer PR, Rappuoli R, Casini D, O'Hagan D, Runham C, Montomoli E, Baudner B, Donnelly Iii JJ, Lapini G, Wack A.

Version 2. PLoS Curr. 2009 Aug 31 [revised 2009 Jan 1];1:RRN1025.

31.

MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT.

Pharm Res. 2009 Jun;26(6):1477-85. doi: 10.1007/s11095-009-9859-5. Epub 2009 Mar 3.

PMID:
19255727
32.

Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A.

Hilleringmann M, Giusti F, Baudner BC, Masignani V, Covacci A, Rappuoli R, Barocchi MA, Ferlenghi I.

PLoS Pathog. 2008 Mar 21;4(3):e1000026. doi: 10.1371/journal.ppat.1000026.

33.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O'Hagan DT.

Vaccine. 2008 Jan 24;26(4):552-61. Epub 2007 Dec 7.

PMID:
18162266
34.

A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.

Vajdy M, Baudner B, Del Giudice G, O'Hagan D.

Clin Immunol. 2007 May;123(2):166-75. Epub 2007 Mar 8.

PMID:
17349825
35.

Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform.

Baudner BC, Verhoef JC, Giuliani MM, Peppoloni S, Rappuoli R, Del Giudice G, Junginger HE.

J Drug Target. 2005 Sep-Nov;13(8-9):489-98.

PMID:
16332574
36.

Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system.

Baudner BC, Morandi M, Giuliani MM, Verhoef JC, Junginger HE, Costantino P, Rappuoli R, Del Giudice G.

J Infect Dis. 2004 Mar 1;189(5):828-32. Epub 2004 Feb 18.

PMID:
14976599
37.

The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.

Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD.

Vaccine. 2003 Sep 8;21(25-26):3837-44.

PMID:
12922117
38.

Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles.

Baudner BC, Balland O, Giuliani MM, Von Hoegen P, Rappuoli R, Betbeder D, Del Giudice G.

Infect Immun. 2002 Sep;70(9):4785-90.

Supplemental Content

Loading ...
Support Center